Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention

Open access
Iqbal, K., Grundke‐Iqbal, I.·2008·Journal of Cellular and Molecular Medicine

Abstract

Introduction Significance Etiopathogenesis Mechanism by which ab normal hyperphosphorylation of tau leads to neurofibrillary degeneration Signal transduction pathways involved Role of decreased brain glucose metabolism in neurofibrillary degeneration Subgroups of AD Therapeutic approaches to inhibit neurofibrillary degeneration Alzheimer disease (AD) is multi‐factorial and heterogeneous. Independent of the aetiology, this disease is characterized clinically by chronic and progressive dementia and histopathologically by neurofibrillary degeneration of abnormally hyperphosphorylated tau seen as intraneuronal neurofibrillary tangles, neuropil threads and dystrophic neurites, and by neuritic (senile) plaques of β‐amyloid. The neurofibrillary degeneration is apparently required for the clinical expression of AD, and in related tauopathies it leads to dementia in the absence of amyloid plaques. While normal tau promotes assembly and stabilizes microtubules, the abnormally hyperphosphorylated tau sequesters normal tau, MAP1 and MAP2, and disrupts microtubules. The abnormal hyperphosphorylation of tau also promotes its self‐assembly into tangles of paired helical and or straight filaments. Tau is phosphorylated by a number of protein kinases. Glycogen synthase kinase‐3 (GSK‐3) and cyclin dependent protein kinase 5 (cdk5) are among the kinases most implicated in the abnormal hyperphosphorylation of tau. Among the phosphatases which regulate the phosphorylation of tau, protein phosphatase‐2A (PP‐2A), the activity of which is down‐regulated in AD brain, is by far the major enzyme. The inhibition of abnormal hyperphosphorylation of tau is one of the most promising therapeutic targets for the development of disease modifying drugs. A great advantage of inhibiting neurofibrillary degeneration is that it can be monitored by evaluating the levels of total tau and tau phosphorylated at various known abnormally hyperphosphorylated sites in the cerebrospinal fluid of patients, obtained by lumbar puncture. There are at least five subgroups of AD, each is probably caused by a different etiopathogenic mechanism. The AD subgroup identification of patients can help increase the success of clinical trials and the development of specific and potent disease modifying drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1582-4934.2008.00225.x

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 238

Metadata

Authors
Iqbal, K., & Grundke‐Iqbal, I.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2008-01
Volume
12
Issue
1
Pages
38-55
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W1515449698
Cited by
238
References
43
FWCI
15.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. https://app.cochat.ai/papers/10.1111/j.1582-4934.2008.00225.x
The paper
Iqbal, K., & Grundke‐Iqbal, I. (2008). Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2008.00225.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.